From the Laboratory for Neurovirology and Microbial
Pathogenesis, Departments of Neurology, Anatomy and Neurobiology, and
Microbiology and Molecular Genetics, University of California,
Irvine, California 92697-4292 and ¶ Institut für
Virologie, D-35392 Giessen, Germany
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Borna disease virus (BDV) causes persistent central nervous system infection and behavioral disturbances in warm-blooded animals. Protein interaction studies were pursued to gain insight into the functions of the putative nucleoprotein (N), phosphoprotein (P), atypical glycoprotein (gp18), and X protein (X) of BDV. Coimmunoprecipitation experiments indicated that N and P, and P and X, form complexes in infected cells. Two-hybrid analyses confirmed interactions between P and P, P and X, and P and N, but not between P and gp18, N and gp18, X and gp18, or X and N. Analysis of P truncation mutants identified three nonoverlapping regions important for oligomerization (amino acids (aa) 135-172), and binding to X (aa 33-115) or N (aa 197-201). Coexpression of X stimulated oligomerization of P but decreased N-P complex formation. Immunocytochemistry of transfected noninfected CHO cells demonstrated that the distribution of X is dependent upon the presence of P-X expressed alone was found predominantly in the cytoplasm whereas coexpression of X and P resulted in nuclear localization. Immunocytochemistry of infected cells revealed nuclear colocalization of P and X. Interactions of P, N, and X may have implications for regulation of BDV transcription/replication and ribonucleoprotein assembly.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Borna disease virus (BDV)1 is a nonsegmented, negative-strand RNA virus that infects a broad range of warm-blooded animal species to cause disturbances of movement and behavior (1-5). The antigenome of BDV contains at least six major open reading frames (ORFs) corresponding to the nucleoprotein (N), phosphoprotein (P), atypical glycoprotein (gp18), type I membrane glycoprotein (G), polymerase, and X-protein (X). Both N and P are abundant in infected cells. N is translated from a monocistronic RNA representing the first transcription unit. P is translated from an RNA representing the second transcription unit that contains coding sequences for both P and X. gp18, G, and polymerase are translated from RNAs generated from the third transcription unit by alternative splicing of one or two introns and are present only at low levels in infected cells (6). BDV replicates in the nucleus of infected cells (7-9). Thus, transport of viral RNA and protein between nucleus and cytoplasm is an essential feature of its life cycle. Nuclear localization signals are proposed for the P (10), N (11), and polymerase proteins (12, 13). In infected cells and tissues, N colocalizes with P and was recently reported to colocalize with X (14).
The phosphoproteins of nonsegmented, negative-strand RNA viruses are essential for virus transcription and replication (7). Their phosphorylation by cellular kinases influences the ability of phosphoproteins to form homomultimers, bind other viral proteins, and serve as transcriptional activators. Here, we characterize the interactions between X, P, and N in vitro and in vivo and define X as a positive regulator of P-P multimerization.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cell Lines-- COS-7 and C6 cells were maintained in Dulbecco's modified Eagle's medium containing 5% fetal calf serum. CHO-AA8 cells that exhibited stable expression of the pTet-off regulatory plasmid (CLONTECH) were grown as monolayer cultures. Sequences encoding P and N were cloned into the pTRE response plasmid and co-transfected with the pTK-HYG selectable marker into CHO-AA8 cells Tet-off (CLONTECH) to create the double stable cell lines CHO-P and CHO-N. All experiments performed in the presence of tetracycline (TCN) employed drug concentrations recommended by the manufacturer and were confirmed not to impact cell viability.
Immunofluorescence-- Forty-eight hours after transfection, cells were fixed with 3% paraformaldehyde for 20 min and permeabilized with 0.5% Triton X-100 (Sigma) for 5 min. After blocking with 3% fraction V bovine serum albumin in 1× phosphate-buffered saline for 15 min, cells were incubated for 60 min with primary antiserum in phosphate-buffered saline plus 1% fetal bovine serum. Monoclonal mouse antibody 24/36F1 (15) diluted 1:1000 was used to detect P, monoclonal mouse antibody p40-17c (15) diluted 1:500 was used to detect N; polyclonal rabbit antiserum diluted 1:200 was used to detect X (14). The specificity of these antibodies was confirmed using CHO-cells expressing N, P, or X. Secondary antibodies included rhodamine isothiocyanate-labeled goat anti-mouse immunoglobulin IgG and fluorescein isothiocyanate-labeled anti-rabbit immunoglobulin IgG (Molecular Probes).
Plasmid Constructions-- The plasmids pGAL4, encoding the DNA-binding domain of GAL4 under the SV40 ori/early promoter control, and pVP16, encoding the VP16 transactivating domain of herpesvirus under the SV40 ori/early promoter control, were provided by A. K. Banerjee. The reporter plasmid pGL-Gs, containing the GAL4 binding site, E1b TATA promotor, and luciferase reporter (luc) gene, were gifts from P. Staeheli. The plasmids pAD424 containing the GAL4 DNA activation domain, pBGT9 containing the DNA binding domain, and pPTRE were purchased from CLONTECH.
Oligonucleotide primers used in PCR to clone wild type and mutant BDV sequences are available on request. Sources of template were: RNA from infected C6 cells (N constructs and X constructs), and plasmids pBluescript-P (P constructs) and pRC/CMV-gp18 (gp18 constructs). The 5' splicing site of intron-1 is mutated in pRC/CMV-M to ensure expression of intact protein (16). GAL4 constructs were cloned using primers containing BamHI (5') or KpnI sites (3') to facilitate cloning into those sites in plasmid pGAL4. VP16 constructs were cloned using primers containing EcoRI (5') or HindIII (3') sites to facilitate cloning into plasmid pVP16. Complete predicted coding sequence for the X ORF was amplified from infected C6 cells by RT-PCR using the primers GAL4-5'(BamHI) and GAL4-3'(KpnI) and cloned into the EcoRV site of pBluescript SKII+ (Stratagene). Thereafter, the X ORF was subcloned into BamHI and KpnI sites of pGAL4 to create pGAL4-X, and into the EcoRI and HindIII sites of pVP16 to create pVP16-X. The X, N, P, and gp18 ORFs were released from the mammalian two-hybrid vectors and subcloned into the yeast two-hybrid vectors pAD424 and pBGT9. The plasmid pBluescript-BDV-X was generated for in vitro translation of X. It contains the X ORF, a ribosomal binding site predicted to enhance X translation relative to wild type sequence, and a mutated BDV-P AUG designed to abrogate expression of the P ORF without disrupting the X ORF. To create pBluescript-BDV-X, the X ORF was amplified by PCR from pBluescript-TA-BDV-X with primers AUG-X(EcoRI) and pET15b(BamHI) and then cloned into pBluescript SKII+. The ribosomal binding sequence of X (ugugAUGa) was adapted by this PCR step to a more favorable consensus sequence (cgccAUGg) (17). Furthermore, the AUG of the P, which is located within the X ORF, was mutated to ACG in two consecutive PCR reactions using AUG-P-anti and AUG-P-sense primers. For stable or transient expression of P, N, and X, the corresponding ORFs were subcloned from pBluescript-BDV-X, pBluescript-BDV-N, and pBluescript-BDV-P into PTRE or pcDNA3.1 vectors.In Vitro Translation of BDV-X, -N, and -P-- The plasmids pBluescript-BDV-X, pBluescript-BDV-P, and pBluescript-BDV-N were linearized with XbaI and used as template for in vitro transcription of RNAs containing the corresponding ORFs. In vitro translation reactions followed standard protocols (Stratagene) and used 500 ng of RNA in a total volume of 50 µl with 10 µCi of [35S]methionine and [35S]cysteine (Express Labeling, NEN Life Science Products).
Immunoprecipitation of in Vivo Labeled BDV Proteins-- Persistently infected and uninfected C6 cells (107) were incubated with 500 µCi of [35S]methionine and [35S]cysteine (Express Labeling, NEN Life Science Products) in Dulbecco's modified Eagle's medium containing 5% fetal calf serum overnight. Cells were washed twice with phosphate-buffered saline on ice, and then incubated with 600 µl of lysis buffer (50 mM Tris-HCl, pH 7.2, 1% Triton X-100, 1% deoxycholic acid (Sigma), 0.1% SDS, 150 mM NaCl) for 10 min on ice. After clearing by centrifugation, samples were split into three aliquots containing 300 µl of lysis buffer and 5 µl of rabbit anti-X serum (14), 5 µl of rabbit anti-P serum (15), or 1 µg of monoclonal N-serum (15) and incubated at 4 °C overnight. After addition of Protein A-Sepharose (Sigma) for 1 h at 4 °C, beads were washed twice with 0.5 ml of lysis buffer and twice with 1 ml of 50 mM Tris-HCl containing 150 mM NaCl. The bound protein was collected by centrifugation and then released by boiling in Laemmli buffer (18). Proteins were size-fractionated by 15% SDS-PAGE for analysis by autoradiography.
In Vitro Binding Assays-- Binding assays were performed using Ni-agarose-bound N and in vitro translated P and X as described by Waterman and colleagues (19).
Mammalian Two-hybrid Assays-- COS-7 cells were transfected with reporter and test plasmids (1 µg) using Lipofectin (Life Technologies, Inc.) in Opti-MEM medium (Life Technologies, Inc.). For three protein interaction studies, the plasmid containing an BDV ORF not fused to VP16 or GAL4 was transfected by the same method except that 5 µg of DNA was used. Forty-eight hours thereafter, cells were lysed in lysis buffer (25 mM Tris-HCl, pH 7.8, 2 mM dithiothreitol, 2 mM EDTA, 10% glycerol, 1% Triton X-100) for 15 min at room temperature. After centrifugation at 15,000 × g for 5 min, the supernatant (cell extract) was collected and the protein concentration was estimated by Bradford assay (Bio-Rad). Five hundred nanograms of total protein in each cell extract were assayed for luciferase activity.
Yeast GAL4 Two-hybrid Assays--
Yeast two-hybrid studies were
pursued using two different strains of Saccharomyces
cerevisiae in accordance with manufacturer protocols (Matchmaker,
CLONTECH). Strain CG1945 (MATa ura3-52, his3-200 ade2-101, lys2-801, trp1-901 leu2-3, 112, gal4-542,
gal80-538,cyhr2, LYS2::GAL1UAS-GAL1TATA-HYS3,
URA#::GAL417merr(X#)-CYC1TATA-LacZ) was used in colony
lift assays. Strain SFY526 (MATa ura3-52, his3-200 ade2-101,
lys2-801, trp1-901 leu2-3, 112rcan, gal4-542, gal80-538, URA3::GAL1-lacZ) was used in -galactosidase assays to
quantify interaction efficiency.
Purification of Recombinant N Protein-- Recombinant BDV -N was expressed in Escherichia coli transformed with plasmid pET-N (15); the resulting histidine-tagged proteins were purified from the soluble supernatant of E. coli by nickel-agarose chromatography as described (20).
Western Immunoblot Analysis of BDV Proteins Expressed in COS-7 Cells-- Lysates of COS-7 cells transfected with BDV expression constructs were size-fractionated using SDS-PAGE (15%) and subjected to Western immunoblot analysis as described previously (21). The expression levels of wild type and deletion mutants of P and N were assayed by using rat and rabbit polyclonal antiserum to N and P (21). Secondary antibodies for western immunoblots were goat anti-rat IgG-alkaline phosphatase (Sigma) or goat anti-rabbit IgG-alkaline phosphatase (Sigma). Binding of antibodies was visualized by chemiluminescence (ECL kit; Amersham Pharmacia Biotech).
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Immunoprecipitation of P-N-X Complexes from BDV-infected
Cells--
To investigate potential interactions between the BDV
proteins P, X, and N, immunoprecipitation experiments were performed with radiolabeled extracts from infected or noninfected C6 cells and
polyclonal rabbit antiserum directed against X and P, or a monoclonal
antibody directed against N. In experiments with extracts from infected
cells, each antiserum/antibody precipitated its cognate antigen and
with varying efficiency two additional BDV proteins: anti-X, X P > N; anti-P, P
N > X; anti-N, N
P
X
(Fig. 1, lanes 2-4). No
proteins similar in size to N, P, or X were precipitated from
noninfected cells (Fig. 1, lanes 5-7).
|
Confirmation of Binding Interactions between BDV Proteins Using Two-hybrid Systems in Mammalian Cells and Yeast-- A GAL4/VP16-based two-hybrid system (22) was used to study the interactions of P with N, gp18, and X in COS-7 cells. Initially, cDNA corresponding to the P ORF was fused to the VP16 transactivating domain (VP16-P) and cDNAs corresponding to the ORFs of P, N, and X were fused to the GAL-4 DNA binding region (GAL4-P, GAL4-N, and GAL4-X). Various combinations of individual constructs and a luciferase reporter plasmid were transfected into COS-7 cells. Forty-eight hours thereafter, luciferase activity was measured in cell extracts as an index to protein-protein interactions (Table I). Transfection of VP16-P and GAL4-N resulted in a 104-fold induction of luciferase activity compared with transfection of the luciferase reporter plasmid alone. Transfection of VP16-P with GAL4-P or VP16-P with GAL4-X resulted in even more pronounced induction of luciferase activity (Table I). In contrast, no interaction was detected between GAL4-N and VP16-X, GAL4-N and VP16-gp18, GAL-4-P and VP16-gp18, GAL4-X and VP16-gp18, or VP16-X and GAL4-X. Oligomerization was observed between GAL4-gp18 and VP16-gp18 (data not shown). Transfection of single BDV ORFs fused to either VP16 or GAL-4 did not result in induction of luciferase activity (data not shown). Protein interactions in the yeast two-hybrid system were similar to those observed in mammalian cells. In colony lift assays, there were strong interactions between P and X; weaker interactions between P and N; and no interactions between N and X, X and X, P and gp18, or X and gp18 (Table II). Quantitation of binding efficiency in B-galactosidase assays revealed 100-fold greater binding between P and X than P and N.
|
|
P Binds to His-tagged N in Vitro-- In vitro binding experiments were pursued to test for BDV protein interactions via a method independent of two-hybrid analyses in mammalian cells and yeast. For this purpose recombinant histidine-tagged N was coupled to Ni-agarose beads and incubated with radiolabeled in vitro translated [35S]methionine-labeled P or X. P bound with high efficiency to N-Ni-agarose beads (Fig. 2, lane 3); P did not bind to Ni-agarose beads alone (Fig. 2, lane 4). X did not bind to either N-Ni-agarose beads (Fig. 2, lane 2) or Ni-agarose beads (Fig. 2, lane 4). Addition of nonlabeled P did not facilitate binding of labeled X to N-Ni-agarose beads (data not shown).
|
Three Distinct Regions of P Are Critical for Its Interaction with N, P, and X-- A series of amino- and carboxyl-terminal truncation mutants of P fused to VP16 were used to investigate the regions of P critical for interaction with N (Fig. 3A). Western immunoblot analysis was used as a control to ensure that levels of expression were similar with all P constructs (data not shown). Deletion of the first 32 or 93 amino acids (aa) from the amino terminus of P resulted in 5-fold or 3-fold higher binding to GAL4-N, respectively, compared with wild type (full-length) VP16-P. Deletion of the first 134 aa of P resulted in a slight decrease (26%) in binding to GAL4-N. In contrast, deletion of 4, 29, 67, or 86 aa from the carboxyl terminus of P abrogated binding to GAL4-N.
|
Binding of X Enhances Oligomerization of P-- To investigate simultaneous interactions between three BDV proteins, two-hybrid analyses were pursued in experiments where a third protein, not fused to either VP-16 or GaL-4, was also present (Table III). Interestingly, coexpression of X markedly enhanced oligomerization of P (4-fold), and had minor impact on VP16-P/GAL4-N interaction (Table III). Coexpression of P or N abrogated binding of VP16-P to GAL4-P, and binding of VP16-P to GAL4-N, respectively (Table III). Binding of VP16-P to GAL4-X was inhibited by coexpression of P, N or X (data not shown).
|
P Facilitates Retention of X in the Nucleus-- To assess the effects of coexpression of individual BDV proteins on their subcellular distribution, TCN-repressible stable CHO cell lines expressing P (CHO-P) or N (CHO-N) were transiently transfected with plasmids encoding X. The distribution of relevant BDV proteins were then examined in the presence or absence of TCN. Whereas suppression of P expression (presence of TCN, Fig. 4A) resulted in cytoplasmic distribution of X (Fig. 4C), expression of P (Fig. 4B) resulted in nuclear distribution of X (Fig. 4D). The distribution of X did not vary with the presence or absence of N (data not shown).
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Recognition of the association of N and P (soluble antigen complex) dates from the earliest attempts to purify BDV proteins from infected cells and tissues (23-25). Although the presence of the soluble antigen continues to be a mainstay in BDV clinical diagnostics, the basis for complex formation and its significance in the virus life cycle remain poorly understood. The experiments reported here define regions along P critical to the N-P interactions, and describe additional interactions between BDV N, P, and X that may provide insight into mechanisms for control of viral transcription/replication and RNP formation.
Co-immunoprecipitation experiments using extracts from infected cells and antibodies directed against P, X, and N indicated interactions between X and P, P and N, and to a lesser extent between X, P, and N. These interactions were confirmed through studies in (i) mammalian and yeast two-hybrid systems that demonstrated specific binding between P and N, P and X, and P and P; (ii) noninfected transfected cells where simultaneous expression of X and P resulted in nuclear localization of X (versus predominantly cytoplasmic localization of X when expression of P was suppressed); and (iii) infected C6 cells where X, P, and N were colocalized in the nucleus.
Analysis of a series of P truncation mutants allowed the identification of three nonoverlapping regions important for P oligomerization (aa 135-172), binding to X (aa 33-115), and binding to N (aa 197-201). The aa of P critical for binding to X were mapped to the amino-terminal portion of the protein between aa 33 and 115. Deletion of the first 32 aa of P resulted in increased binding of X, indicating that this region behaves as a negative regulatory domain. The binding of X and P was increased 7-fold in assays using a P mutant in which the oligomerization domain was deleted. This suggests that X binds preferentially to the monomeric form of P. Based on this finding, we anticipated that binding of X to P would inhibit P oligomerization. Intriguingly, the converse was observed; binding of X to P enhanced P oligomerization. In other nonsegmented negative strand RNA viruses, oligomerization of phosphoproteins correlates with viral transcriptional activity (26, 27). Colocalization of X and P in the nucleus of chronically infected cells indicates that X is associated with P at the sites of virus replication and transcription. Taken together, these data suggest the possibility that X may modulate transcriptional activity of BDV via binding to P.
We reported previously that multimerization of P in vitro is dependent upon disulfide bridging of cysteines at aa position 125 in P monomers (15). Although we cannot exclude the possibility that disulfide bridges play a role in P multimerization in some cellular compartments in vivo, it is unlikely that this mechanism applies in the highly reducing environment of the cytoplasm (28, 29). In the two-hybrid system, the critical region for interaction of P with itself was not found at Cys-125 but was instead localized toward the carboxyl-terminal portion of the protein. Deletion of 4 or 26 aa from the carboxyl terminus resulted in a less than 50% decrease in binding. A complete abrogation of binding was observed in P mutants lacking 67 or 86 aa at the carboxyl terminus.
It is possible that phosphorylation is involved in BDV-P homomultimer formation as has been suggested for the phosphoprotein of vesicular stomatitis virus (27, 30). P is predominantly phosphorylated in vitro and in vivo at serine residues in the amino-terminal portion of the protein (31, 32). It is intriguing to speculate that phosphorylation of serine residues within the negative regulatory domain of P (first 32 aa of P) (32) may be responsible for modulating binding of P to X and N. Accordingly, deletion of this region may mimic nonphosphorylated P, which exhibits a higher binding efficiency to X and N. Whether lack of phosphorylation in the yeast two-hybrid system causes the 100-fold higher binding efficiency of P-X complexes compared with P-N complexes remains to be shown. The presence of the negative regulatory domain in the mammalian two-hybrid system had no substantive influence on the capacity of P to bind to itself. If the function of this domain is dependent upon phosphorylation, our model would predict that phosphorylation should not significantly influence oligomerization of BDV-P. Indeed, recent studies indicate that nonphosphorylated P expressed in E. coli is competent for oligomer formation (15).2
The last 4 carboxyl-terminal aa of P were found to be critical for its interaction with N (deletion eliminated binding to N). In this respect BDV is similar to respiratory syncytial virus, where the last 20 carboxyl-terminal aa of the phosphoprotein are essential for interaction with the nucleoprotein (33). No similar terminal region is defined in the phosphoprotein of vesicular stomatitis virus, although the last 5 carboxyl-terminal aa the of the nucleoprotein are essential for binding to the phosphoprotein (22).
The nuclear localization of BDV replication and transcription requires provisions for bidirectional transport of viral proteins and RNAs across the nuclear membrane. Although it is formally possible that each of the BDV proteins has its own signals for bidirectional transport, an alternative system would allow proteins to traffic together in complexes. Recent work has shown the presence of a functional nuclear export sequence in X (34) and suggests the speculation that X may facilitate nuclear export of ribonucleoprotein complexes in a manner similar to the NS2 protein of influenza virus (35). Support for this notion is found in the coimmunoprecipitation and colocalization experiments, which indicated an association between P and N, proteins predicted to be components of the RNP, and X. Efforts to find in vitro evidence for association of N and X were not successful. X did not bind to N in the two-hybrid systems or the in vitro binding assay using N-Ni-agarose alone or N-Ni-agarose in the presence of P. It is conceivable that higher affinities of P for X and N for P obscure detection of complexes comprising P, N, and X. Indeed, the affinity of the three protein complex may be lower in vitro because additional components (for example genomic RNA) are absent. This hypothesis has not been tested because methods are not established for purification of BDV RNPs. However, two-hybrid studies identified three distinct regions of P that could allow simultaneous interaction of P with itself, N, and X (Fig. 3B), suggesting a mechanism whereby P could bridge N and X to facilitate a complex of the three proteins.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank B. De, R. O. O'Neill, N. Fischer, and I. Jordan for comments.
![]() |
FOOTNOTES |
---|
* This work was supported by a stipend (to M. S.) and Grant SFB-535 (to J. R.) from the Deutsche Forschungsgemeinschaft and Grant NS-29425 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ These three authors contributed equally to this work.
To whom correspondence should be addressed: Laboratory for
Neurovirology and Microbial Pathogenesis, 3rd Fl., Gillespie Bldg., University of California, Irvine, CA 92697-4292. Tel.: 714-824-6193; Fax: 714-824-1229; E-mail: ilipkin{at}uci.edu.
1 The abbreviations used are: BDV, Borna disease virus; aa, amino acid(s); ORF, open reading frame; TCN, tetracycline; CHO, Chinese hamster ovary; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis.
2 M. Schwemmle and W. I. Lipkin, unpublished data.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|